Efficacy and safety of oral AMN107 [nilotinib] in adults with chronic myelogenous leukemia resistant and/or intolerant to imatinib mesylate therapy
Phase of Trial: Phase II/III
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Nilotinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Therapeutic Use
- 01 Sep 2009 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual number of patients (36) added as reported by ClinicalTrials.gov.
- 01 Sep 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.